Karyopharm Therapeutics Inc. Common Stock (KPTI) Stock
Fundamentals
Recent news

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates
KPTI

Why Is KPTI Stock Down 69% After-Hours Today?
Why Is KPTI Stock Down 69% After-Hours Today?
KPTI

Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?
Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?
KPTI

Wall Street Analysts Think Karyopharm Therapeutics (KPTI) Could Surge 70.46%: Read This Before Placing a Bet
Wall Street Analysts Think Karyopharm Therapeutics (KPTI) Could Surge 70.46%: Read This Before Placing a Bet
KPTI
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates
KPTI

Why Is KPTI Stock Down 69% After-Hours Today?
Why Is KPTI Stock Down 69% After-Hours Today?
KPTI

Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?
Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?
KPTI

Wall Street Analysts Think Karyopharm Therapeutics (KPTI) Could Surge 70.46%: Read This Before Placing a Bet
Wall Street Analysts Think Karyopharm Therapeutics (KPTI) Could Surge 70.46%: Read This Before Placing a Bet
KPTI

Karyopharm Therapeutics Q1 Earnings Call Highlights
Karyopharm Therapeutics Q1 Earnings Call Highlights
KPTI

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates
KPTI

Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?
KPTI

KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data
KPTI

KPTI Stock Slumps Pre-Market Even As Karyopharm’s Myelofibrosis Treatment Meets Primary Endpoint — Retail Doubtful About FDA Approval
KPTI Stock Slumps Pre-Market Even As Karyopharm’s Myelofibrosis Treatment Meets Primary Endpoint — Retail Doubtful About FDA Approval
KPTI

Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study
Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study
KPTI
About Karyopharm Therapeutics Inc. Common Stock
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Richard A. Paulson M.B.A. | President, CEO & Director | 1967 |
| Mr. Stuart Poulton | Executive VP & Chief Development Officer | 1973 |
| Dr. Reshma Rangwala M.D., Ph.D. | Executive VP, Chief Medical Officer & Head of Research | 1978 |
| Dr. Sharon Shacham M.B.A., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | 1970 |
| Ms. Lori A. Macomber CPA | EVP, CFO & Treasurer | 1971 |
| Ms. Kristin Abate | VP, Chief Accounting Officer & Assistant Treasurer | — |
| Mr. Brendan Twohig Strong | Senior Vice President of Investor Relations | — |
| Mr. Michael J. Mano J.D. | Executive VP, Chief Legal Officer & Secretary | 1977 |
| Mr. James Accumanno J.D. | Chief Compliance Officer | — |
| Ms. Lisa DiPaolo | Executive VP & Chief Human Resource Officer | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
2 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +49.1 | -41.9 | +42.8 | +3.8 | -0.5 | -79.9 | +4.6 | -12.4 |



